Poorly Soluble Drugs - Dissolution and Drug Release
by Gregory K. Webster (AbbVie Inc., USA), Derek Jackson (Cubist Pharmaceuticals, USA), Robert Bell (Drug & Biotechnology Development LLC, USA)
Hardback 703 pages 2017-01-31 Print ISBN: 9789814745451 eBook ISBN: 9789814745468 DOI: 10.4032/9789814745468
List price : $249.95
“Even those who have been developing dissolution methods for years will find valuable information, since this text goes well beyond the basics of dissolution development for poorly soluble drugs. . . . The book walks through the lifecycle of a dissolution method for a poorly soluble compound, starting with solubility and intrinsic dissolution, including use of surfactants, has chapters that address several of the strategies used for formulation development and the staged approach to development of dissolution methods, provides chapters on alternatives to the traditional USP dissolution Apparatus 1 and 2, including Apparatus 3 and 4 and noncompendial approaches, then moves to some of the most interesting information describing biorelevant dissolution, clinically relevant dissolution, QbD approaches, and regulatory considerations. . . . Overall, this is a book that I strongly recommend for everyone involved in dissolution method development. It goes into much greater detail than similar texts and provides practical information that will prove helpful in addressing the concepts presented, both from a scientific and a regulatory perspective.”
Gregory Martin - Dissolution Technologies
This book is the first text to provide a comprehensive assessment of the application of fundamental principles of dissolution and drug release testing to poorly soluble compounds and formulations. Such drug products are, vis-à-vis their physical and/or chemical properties, inherently incompatible with aqueous dissolution. However, dissolution methods are required for product development and selection, as well as to fulfill regulatory obligations with respect to biopharmaceutical assessment and product quality understanding. The percentage of poorly soluble drugs, defined in classes 2 and 4 of the Biopharmaceutics Classification System (BCS), has significantly increased in the modern pharmaceutical development pipeline. This book provides a thorough exposition of general method development strategies for such drugs, including instrumentation and media selection, the use of compendial and non-compendial techniques in product development, and phase-appropriate approaches to dissolution development. Emerging topics in the field of dissolution are also discussed, including biorelevant and biphasic dissolution, the use on enzymes in dissolution testing, dissolution of suspensions, and drug release of non-oral products. Of particular interest to the industrial pharmaceutical professional, a brief overview of the formulation and solubilization techniques employed in the development of BCS Class 2 and 4 drugs to overcome solubility challenges is provided and is complimented by a collection of chapters that survey the approaches and considerations in developing dissolution methodologies for specific enabling drug delivery technologies, including nanosuspensions, lipid-based formulations, and stabilized amorphous drug formulations.
About the Editors:
Gregory K. Webster is a senior principal research scientist with AbbVie Inc.’s Global Analytical Research and Development. He obtained his BS in chemistry from St. Xavier College, USA, MS in analytical chemistry from Governors State University, USA, and PhD in analytical chemistry from Northern Illinois University. Dr. Webster’s industrial career spans an employment history with several major pharmaceutical companies. His first book with Pan Standard, Supercritical Fluid Chromatography: Advances and Applications in Pharmaceutical Analysis, was published in 2014.
Robert G. Bell is president of Drug and Biotechnology Development LLC, USA, a consultancy to the pharmaceutical industry and academia for biological, drug, and device development. He received his education from the University of Florida and has worked with the pharmaceutical industry for over 30 years. Dr. Bell is adjunct faculty at Virginia Commonwealth University and the University of Florida College of Pharmacy and is a member of the Council of Experts, General Chapters—Biological Analysis for United States Pharmacopeia.
J. Derek Jackson is director of Analytical Development at Flexion Therapeutics Inc, USA. He earned his BS and MA in chemistry from the College of William and Mary in Virginia. Derek has been engaged in all stages of pharmaceutical discovery, research, and development for 20 years, in both large pharma and small-to-mid-cap biotech companies.
|1||Chapter 1: The Modern Pharmaceutical Development Challenge: BCS Class II and IV Drugs|
Gregory K. Webster, Robert G. Bell, and J. Derek Jackson
|19||Chapter 2: Solubility Determinations for Pharmaceutical API|
Kofi Asare-Addo and Barbara R. Conway
|85||Chapter 3: Use of Surfactants in Dissolution Testing|
|105||Chapter 4: Intrinsic Dissolution Evaluation of Poorly Soluble Drugs|
Michele Georges Issa and Humberto Gomes Ferraz
|125||Chapter 5: Oral Delivery of Poorly Soluble Drugs|
Dev Prasad, Akash Jain, and Sudhakar Garad
|187||Chapter 6: A Staged Approach to Pharmaceutical Dissolution Testing|
Gregory K. Webster, Xi Shao, and Paul D. Curry, Jr.
|209||Chapter 7: Development and Application of in vitro Two-Phase Dissolution Method for PoorlyWater-Soluble Drugs|
Ping Gao, Yi Shi, and Jonathan M. Miller
|235||Chapter 8: The Use of Apparatus 3 in Dissolution Testing of Poorly Soluble Drug Formulations|
G. Bryan Crist
|255||Chapter 9: Use of Apparatus 4 in Dissolution Testing, Including Sparingly and Poorly Soluble Drugs|
Rajan Jog, Geoffrey N. Grove, and Diane J. Burgess
|301||Chapter 10: Dissolution of Nanoparticle Drug Formulations|
|353||Chapter 11: Dissolution of Lipid-Based Drug Formulations|
Stephen M. Cafiero
|393||Chapter 12: Dissolution of Stabilized Amorphous Drug Formulations|
Justin R. Hughey
|419||Chapter 13: Dissolution of Pharmaceutical Suspensions|
Beverly Nickerson, Michele Xuemei Guo, Kenneth J. Norris, and Ling Zhang
|455||Chapter 14: Dissolution Testing of Poorly Soluble Drugs: “Biorelevant Dissolution”|
Mark McAllister and Irena Tomaszewska
|511||Chapter 15: Clinically Relevant Dissolution for Low-Solubility Immediate-Release Products|
Paul A. Dickinson, Talia Flanagan, David Holt, and Paul W. Stott
|553||Chapter 16: The QbD Approach to Method Development and Validation for Dissolution Testing|
Alger D. Salt
|573||Chapter 17: Regulatory Considerations in Dissolution and Drug Release of BCS Class II and IV Compounds|
Robert G. Bell and Laila Kott
|603||Chapter 18: Dissolution of Liquid-Filled Capsules Based Formulations|
Rampurna Prasad Gullapalli
|661||Chapter 19: Current and Emerging Non-compendial Methods for Dissolution Testing|
Namita Tipnis and Diane J. Burgess
Industry, Government, Academia
The characters you copied from the image are incorrect. Please try again.